Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 32 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/8/2007 First Published: 6/1/1996


1.		Phase III Randomized Study of Antiandrogen Withdrawal Alone vs Antiandrogen Withdrawal plus Ketoconazole and Hydrocortisone for Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age				NCI				CLB-9583 NCT00002760, CALGB-9583

Last Modified: 1/28/2004


2.		Phase III Study of Chemo/Hormonal Therapy vs Androgen Ablation Alone as Initial Therapy in Patients With Unresectable/Metastatic Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified				NCI				MDA-DM-95231 NCI-G96-1044, NCT00002855

Last Modified: 1/25/2008 First Published: 12/1/2001


3.		Phase III Randomized Study of Second-Line Hormonal Therapy (Ketoconazole and Hydrocortisone) Versus Combination Chemotherapy (Docetaxel and Estramustine) in Asymptomatic Patients With Prostate Cancer and a Rising Prostate-Specific Antigen After Androgen Suppression

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-E1899 SWOG-E1899, CALGB-E1899, E1899, NCT00027859

Last Modified: 1/25/2008 First Published: 2/1/2002


4.		Phase III Randomized Study of Androgen Blockade With Concurrent Chemotherapy Versus Delayed Chemotherapy in Patients With High-Risk Hormone-Naive Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				RTOG-P-0014 RTOG-DEV-1028, ECOG-RTOG-P-0014, CALGB-RTOG-P-0014, SWOG-RTOG-P-0014, NCT00030654


5.		Phase III Management and Prophylaxis of Fever and Infection with Antimicrobial Treatment in Cancer Patients (Study III)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				no age specified								NCI-81-C-189 NCI-POB-8103


6.		Phase III MOX/AMK vs MOX/PIP for Suspected Infection in Febrile, Granulocytopenic Cancer Patients, with Amphotericin-B or Ketoconazole for Failures

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				no age specified								UMCC-8107

Last Modified: 4/21/2008


7.		Phase I/II Study of IL-1A/MITO with Ketoconazole for Metastatic Colorectal and Prostate Carcinomas (Summary Last Modified 08/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Completed				18 and over				NCI				CRB-9202 NCI-T94-0090N, T94-0090

Last Modified: 11/11/2008 First Published: 10/25/2004


8.		Phase I/II Study of Ixabepilone and Ketoconazole in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				AECM-03099 AECM-CA163402, AECM-NMC-03-10-277C, NCT00096317

Last Modified: 12/2/2008 First Published: 9/26/2007


9.		Phase I/II Study of Calcitriol, Ketoconazole, and Hydrocortisone in Patients With Advanced or Recurrent Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				RPCI-I-68905 I 68905, NCT00536991

Last Modified: 4/1/1995


10.		Phase II Randomized Study of Ketoconazole vs DOX/Ketoconazole in Hormone-Refractory Prostate Carcinoma (Summary Last Modified 04/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				MDA-DM-95010 NCI-T95-0012D, T95-0012

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute